Navigation Links
Bone Biologics Announces Another Round of Equity and Debt Investment by Musculoskeletal Transplant Foundation and the Addition of Board Member, Mark Spilker
Date:3/10/2010

THOUSAND OAKS, Calif., March 10 /PRNewswire/ -- Bone Biologics, Inc. announced today it had received another round of investment for preferred shares from the Musculoskeletal Transplant Foundation (MTF). MTF now owns 51% of Bone Biologics. As part of the financing, MTF also provided a line of credit to fund continuing operations.  This financial support continues the investments by MTF that have allowed Bone Biologics, Inc. to progress from research through development of the NELL-1 protein sequence UCB-1 to the current culmination of:

  • Therapeutic validation in non-human primate trials
  • Economic manufacturing of cGMP grade product
  • Patent protected portfolio of claims

The platform technology will be subject to the FDA review and approval process, including clinical trials.  It is not currently approved for use in humans.

Additionally, Mark Spilker, PhD, MTF's Vice President, Research & Development, has been elected to the Bone Biologics, Inc. Board of Directors. Over his career, Dr. Spilker has been responsible for leading development and program management teams in the areas of tissue-engineered biologics, electro-mechanical devices, and electronics. He has launched many new products and served as a company resource for best practices in product development and design controls.

He holds a Bachelor of Science degree in Mechanical Engineering from the University of Utah. He also attended Massachusetts Institute of Technology where he earned both a Master of Science and a Doctor of Philosophy in Mechanical Engineering.

Bruce A. Hazuka, President and CEO of Bone Biologics, Inc. said, "We very much appreciate the continued support of MTF and believe that the experience of Mark Spilker will add expertise to our research, development, and ultimate commercialization of our unique UCB-1 protein."

Musculoskeletal Transplant Foundation

MTF is a non-profit service organization dedicated to providing quality tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families. In 2009, MTF distributed over 415,000 tissue grafts.

Bone Biologics, Inc.

Bone Biologics is a convergence biotechnology company focused in the orthobiologics space.  The company was founded in 2004 by the research scientists who had identified and validated the product in the lab over the previous ten years.  The acquisition of an exclusive worldwide license from UCLA and the both the financing and strategic support from MTF was the genesis of the development of this recombinant protein.

For information: Bruce A. Hazuka/Bone Biologics/818-324-2742

SOURCE Bone Biologics, Inc.

Back to top
'/>"/>
SOURCE Bone Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
2. In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market
3. Dendreon Completes Submission of Biologics License Application for PROVENGE
4. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
5. Crescendo Biologics Raises GBP4.5 million in Seed-Funding Led by Sofinnova Partners
6. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis
7. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
8. Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
9. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
10. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
11. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... (PRWEB) , ... July 25, ... ... pleased to welcome Chuck Heinz as Executive Director of Strategic Planning. His ... the Benchworks team. , Chuck’s professional experience encompasses marketing and differentiation consulting, ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... that the stock market news outlet had initiated coverage on Interpace Diagnostics. ... screens and identifies exposure, progression and risk analysis from specific cancers in ...
(Date:7/20/2017)... ... 2017 , ... VIC Technology Venture Development™ (VIC™), is pleased to ... This addition continues to strengthen and diversify VIC’s board. , "We are excited to ... a highly accomplished business executive with a broad range of experience directly relevant to ...
(Date:7/18/2017)... ... July 18, 2017 , ... Nanomedical Diagnostics, a cutting-edge life ... launch of a new NTA biosensor chip for use with its label-free Agile ... of polyhistidine-tagged (His-tagged) molecules quickly and reliably. , “Recombinant proteins are an ...
Breaking Biology Technology:
(Date:5/6/2017)... 5, 2017 RAM Group , ... new breakthrough in biometric authentication based on a ... properties to perform biometric authentication. These new sensors are ... created by Ram Group and its partners. This sensor ... supply chains and security. Ram Group is a ...
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):